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ÖZET
Amaç: Bu çalışmanın amacı, etkin iyi planlanmış bir ekip yaklaşımının fibrinolitik tedavi almış akut ST-segment yükselmeli miyokart enfarktüslü 
(STEMİ) vakaların sağkalımına etkisini araştırmaktı.
Yöntemler: Fibrinolitik tedavi akut STEMI’lı olgularda akılcı bir seçenek olmaya devam etmektedir. Fibrinolitik tedavi alan STEMI’lı olguların kısa 
sürede tedaviye ulaşmalarının mortalitelerini azalttığı defalarca gösterilmiştir. Nisan 2007’de iyi planlanmış bir ekip yaklaşımı başlatıldı. 
Sosyodemografik, klinik, laboratuvar ve zaman ölçümleri gibi bilgiler 109 çalışma hastasında prospektif olarak, 2005-2007 yıllarından 155 kontrol 
hastasında retrospektif olarak toplandı. Olguyu tartışmak için tek telefon konuşması yapıldı. Acil değerlendirme kesin olgularda yapılmadı. 
Şüpheli olgularda EKG’ler kardiyoloğa fakslandı. Kapı-iğne zamanları medyan olarak hesaplandı. Mortalite oranları kliniğe kontrole gelen has-
talarda kayıtlar incelenerek, diğer tüm hastalarda telefon görüşmeleri ile belirlendi. Kapı-iğne zamanları Mann-Whitney U testi ile karşılaştırıldı. 
Altı aylık mortaliteler Fischer'in tam testi ile karşılaştırıldı.
Bulgular: Çalışma grubunda kapı-iğne aralığı başvurma zamanından bağımsız anlamlı olarak azaldı (mesai dışında 59 dakikadan 29 dakikaya 
azaldı) (mesai içinde 35 dakikadan 18 dakikaya azaldı) (p<0.0001). Mortalite çalışma grubunda (2 ölüm, %1.8) kontrol grubu (12 ölüm, %7.7) ile 
karşılaştırıldığında anlamlı olarak azaldı (p=0.048).
Sonuç: Akut ST yükselmeli miyokart enfarktüsü ile başvuran ve fibrinolitik tedavisi uygulanan hastaların ölüm oranları optimal hastane planla-
ması ile azalmıştır. (Anadolu Kardiyol Derg 2010 Aralık 1; 10(6): 508-13)
Anahtar kelimeler: ST segment yükselmeli miyokart enfarktüsü, mortalite, iyi planlanmış ekip yaklaşımı 
ABSTRACT
Objective: Fibrinolytic therapy remains a legitimate option for many patients presenting with acute ST-segment elevation myocardial infarction 
(STEMI). Shorter time- to- treatment for patients with STEMI administered fibrinolytic therapy has repeatedly been shown to reduce mortality. 
A well-organized collaborative team approach was implemented in April 2007. The purpose of this study was to examine the effect of implement-
ing a well-organized collaborative team approach on the outcome in patients with acute STEMI treated with fibrinolysis. 
Methods: Sociodemographic, clinical, laboratory, and time interval data were prospectively collected on 109 consecutive patients (the study 
group) and 155 patients from the years 2005–2007 (the control group) retrospectively. A single-phone call was made to discuss case. Emergency 
department evaluation was bypassed for definitive case. An electrocardiogram was faxed to the on-call cardiologist for suspected case. Door-
to-needle times were calculated as medians. Mortality was assessed by reviewing records of all patients visiting outpatient clinic. For the rest, 
information was obtained over the phone. Median door-to-needle times were compared using Mann-Whitney U test. The Fisher’s exact test 
was used to compare 6-month mortalities.
Results: Improvements were seen in door-to- needle times in the study group regardless of time of presentation (reduced from 59 minutes to 29 
minutes during off hours) (reduced from 35 minutes to 18 minutes during regular hours) (p<0.0001). Mortality was significantly reduced in the 
study group (2 deaths, 1.8%) compared with the control group (12 deaths, 7.7%, p=0.048).
Conclusion: The mortality of patients presenting with acute STEMI treated with fibrinolytic therapy was significantly reduced after optimal 
hospital organization. (Anadolu Kardiyol Derg 2010 December 1; 10(6): 508-13)
Key words: ST-segment elevation myocardial infarction, mortality, well-organized collaborative team approach 
Introduction
Mortality from ST-segment elevation myocardial infarction 
(STEMI) remains high. Shorter time to reperfusion in patients 
with STEMI treated with fibrinolytic therapy is associated with 
better survival (1-4).
The rapid restoration of sustained patency of the infarct-
related artery with low residual stenosis is the primary goal of 
treatment. This can be achieved by prompt use of either fibrino-
lytic therapy or primary angioplasty. Even in the Western world-
wide application of a primary angioplasty strategy to the major-
ity of patients with acute myocardial infarction (MI) is not fea-
sible. Yet almost one-third of eligible patients is not given any 
reperfusion therapy at all (5). For many such patients, fibrinolytic 
therapy remains a legitimate option. Published guidelines 
recommend a goal of 30 minutes for presentation at the hospital 
to the administration of fibrinolytic therapy (door-to-needle time) 
(6). No contemporary report exists about state or university hos-
pital performance in achieving this goal for time to reperfusion in 
Turkey. In addition, the relation between the time to treatment 
and optimal hospital organization, and its impact on outcome 
have not been well studied. 
Accordingly, the aim of this report was to examine the clini-
cal outcome after the implementation of a well-organized col-
laborative team approach in patients with acute MI treated with 
fibrinolysis. 
Methods
Study design and patient’s characteristics
Patients (n=109) who presented to Servergazi State Hospital 
with STEMI, received fibrinolytic therapy as the reperfusion 
strategy and were managed according to collaborative approach 
(since April 2007, see below) comprised the study group (pro-
spective follow-up group). Patients presenting with ongoing 
chest pain of ≤12 h in duration with ECG criteria of ST-segment 
elevation ≥0.1 mm in two or more electrocardiographic leads 
were assigned to receive either streptokinase or tissue- plas-
minogen activator (t-PA). Patients presenting with uncomplicat-
ed inferior MI with onset of symptoms within 3 hours before the 
initiation of therapy had received streptokinase. All other patients 
had received t-PA. Patients with previous MI, prior coronary 
stenting or coronary artery bypass grafting (CABG), previous 
history of angina pectoris, chronic renal insufficiency, chronic 
obstructive pulmonary disease, stroke, Killip class >1, current 
smoking status, heart rate ≥120 bpm were excluded. Patients 
who had developed stroke, re-ischemia, reinfarction, or died 
during index hospitalization were also excluded. Electronic 
records of all patients who visited our outpatient clinic were 
reviewed. For all other patients, information was obtained by 
direct telephone interview with the patient or relative. 
One hundred and fifty five patients with similar demographic 
and clinical characteristics who had been treated with fibrino-
lytic therapy between August 2005 and March 2007 served as 
controls (restrospective analysis group). 
All patients had received aspirin, β blockers, angiotensin-
converting enzyme inhibitors/ angiotensin receptor blockers, 
and statins while at the hospital and after discharge unless they 
were not tolerated or contraindicated. Clopidogrel could only be 
given for a month after discharge due to government’s reim-
bursement policies. 
Collaborative team approach protocol (Fig. 1)
We implemented a protocol to improve timeliness of reperfu-
sion therapy. 
The protocol was implemented in April 2007 and included the 
following strategies: (1) single-phone call for the on-call cardi-
ologist and the emergency room (ER) physician to discuss case; 
(2) bypassing of emergency department evaluation for definitive 
case; (3) Electrocardiograms were faxed to the on-call cardiolo-
gist for suspected case; (4) multiple consultations were avoided; 
(5) Coronary care unit (CCU) and ER staff were educated and 
trained by a cardiologist; (6) One of the elevators was assigned 
for emergency use only; (7) Transfer of patients carried out by 
the CCU personnel. 
The time period from hospital arrival to time of therapy 
can be influenced readily by changes in hospital practice pat-
terns (7). Our well-organized collaborative team approach is 
shown in Figure 1. A cardiologist had seen patients when asked 
during regular hours (8 AM to 5 PM Monday through Friday), and 
after a decision for pharmacologic reperfusion was made then 
the patient was admitted to the CCU. When 112 was contacted 
for a patient during off hours (5 PM to 8 AM and at weekends), 
and if there was no question regarding diagnosis after initial 
evaluation by 112 personnel or ER personnel, the patient was 
admitted to the CCU. Suspected cases were also brought to the 
ER by 112 for further evaluation, and ER physicians contacted 
the cardiologist on call. Electrocardiograms (ECG) were faxed to 
an off-site cardiologist’s notebook for confirmation. Multiple 
consultations were avoided. Based on the discussion with a 
cardiologist, a decision for pharmacologic or catheter based 
therapy was made. In-hospital treatment delay has been short-
ened to ≈20-30 min by establishing special in-hospital structures 
(8). The CCU and ER staff were educated and trained specifi-
cally on ECG findings and treatment of acute STEMI. One of the 
elevators was assigned to emergency use only. The transfer of 
the patients was carried out by the CCU staff.
Before April 2007, the protocol strategies were not used 
routinely at Servergazi State Hospital. Patients who served as 
controls underwent emergency department evaluation. Multiple 
consultations were made. Some ER personnel were unaware of 
treatment delays associated with increased mortality in patients 
with STEMI treated with fibrinolytic therapy. Previously, ECGs 
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were faxed from the CCU instead of the ER. No elevator was 
assigned for emergency use only. Most patients were trans-
ferred to the CCU by busy ER staff. All of these had caused 
additional delays in time to treatment. 
Data collection 
Our main outcome measure was 6-month mortality. Data 
were obtained on all 264 patients admitted with STEMI and 
received fibrinolytic therapy. Time- to- treatment for fibrinolytic 
therapy was measured with door-to-needle (DTN) time. DTN 
time is the time in minutes between first hospital arrival and the 
delivery of reperfusion therapy. DTN times were calculated as 
medians. Patient demographic and clinical characteristics 
included sociodemographic variables (gender, age); medical his-
tory (hypertension, diabetes, dyslipidemia); the admission time 
of day (day, evening, or night); and admission day of week 
(weekday or weekend), the presence of chest pain, the location 
of myocardial infarction, the fibrinolytic agent used, the percent-
ages of post-fibrinolytic TIMI-3 flow, and post-fibrinolytic CABG. 
Angiographic data analysis
All angiograms were analyzed by an experienced interven-
tional cardiologist blinded to all data apart from the coronary 
angiogram. TIMI (Thrombolysis In Myocardial Infarction) flow 
was assessed, as described previously (9).
Clinical outcomes
Records of all patients who visited our outpatient clinic were 
reviewed. For all other patients, information was obtained by 
direct telephone interview with the patient. At approximately 6 
months after hospital discharge, patients were contacted to 
ascertain vital status. 
Figure 1. Schematic of optimal hospital organization
112 - emergency medical services, CCU - coronary care unit, ECG - electrocardiogram, ER - emergency room, STEMI - ST - elevation myocardial infarction
Patient calls 112 for chest pain Patients presenting with chest pain themselves
Initial ER evaluation with ECG
ECGs are faxed to an off-site
cardiologist for suspected cases
Patients with 'suspected STEMI' are
transported to the ER and ECGs are
faxed to the on-call cardiologist's
notebook
Cardiologist interprets ECGs
in his notebook ond triages
patients, accordingly
ECG suggestive of STEMI as
interpreted by ER staff
Direct CCU admission
(transferred by the CCU staff)
Definitive STEMI, patient bypasses ER
Bed availability in the CCU is checked by 112 
control center
ECG monitoring suggestive of STEMI as
interpreted by 112 personnel
112 arrival and initial evaluation in the field
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Statistical analysis
Statistical analysis was conducted using SPSS version 15.0 
for Windows (SPSS Inc., Chicago, IL, USA). Median door-to-
needle times in the control (pre-protocol) and the study (post-
protocol) groups were compared using a Mann-Whitney U test. 
The Fisher’s exact test was used to compare pre-protocol and 
post-protocol 6-month mortalities. Statistical significance was 
set at a level of p<0.05.
Results
The characteristics of the patients in the study group (n=109) 
and the control group (n=155) are displayed in Table 1. Both groups 
had similar ages and similar percentages of men, hypertension, 
diabetes, dyslipidemia, chest pain, and anterior wall infarctions on 
presentation, the use of streptokinase as the fibrinolytic agent, 
and similar percentages of TIMI-3 flow restoration, and the need 
for coronary artery bypass grafting. Time interval measurements 
according to time of day are presented in Table 2. For groups the 
study and the control, median (25th and 75th percentiles) door-to-
needle times were 29 (19, 37) and 59 (31, 93) minutes during off 
hours (p<0.0001); 18 (12, 26) and 35 (22, 74) minutes during regular 
hours (p<0.0001), respectively. 
Mortality was significantly reduced in the study group (2 
deaths, 1.8%) compared with the control group (12 deaths, 7.7%, 
p=0.048) (Table 1). 
Discussion
The principal novel finding of this study was that by reducing 
time to treatment with the implementation of a well-organized 
in-hospital pharmacological reperfusion strategy, we have posi-
tively influenced our patients’ outcomes. 
Treatment with fibrinolytic therapy remains the most common 
mode of reperfusion for patients presenting with STEMI (10, 11). 
Yet fibrinolytic therapy is a missed opportunity for many patients, 
especially those in rural areas, requiring long transportation times 
to the referral hospitals. Fibrinolytic agents are most effective 
when administered within 2 to 3 hours from symptom onset (12-15) 
with longer treatment delays leading to worse clinical outcomes 
(16). Because it requires at least an additional 30-45 minutes from 
the beginning of treatment until successful vessel reperfusion (17). 
Time-to-treatment for STEMI are still prolonged. Throughout the 
last decade, time-to-treatment remained unchanged for patients 
treated with fibrinolysis (18). Infarct size is significantly affected 
by the duration of coronary occlusion (19-21). Therefore, late 
reperfusion is expected to result in less myocardial salvage and 
a higher mortality rate. De Luca et al. (22) found that patients 
with successful reperfusion had a significantly shorter ischemic 
time. Early reperfusion with fibrinolytic therapy in patients with 
evolving acute myocardial infarction (MI) has been clearly 
demonstrated to reduce mortality and salvage myocardium (23). 
Early and sustained patency of the infarct-related artery has 
been related to improved in-hospital and late survival (24, 25), 
recovery of left ventricular function (24, 26-28), prevention of 
ventricular aneurysm formation (29), and cardiac rupture (30), 
and enhanced electrical stability (31). In addition, previous stud-
ies have demonstrated that only the acute restoration of TIMI 
grade 3 flow, present in ≈50% to 60% of vessels after fibrinolysis, 
is independently predictive of in-hospital survival and reduction 
in infarct size (26, 32, 33). It has been demonstrated that treat-
ment delays with fibrinolytic therapy were associated with 
higher 6-month mortality in patients with STEMI receiving reper-
fusion therapy. 
Variables Control  Study p*
 Subjects Subjects 
 (n=155) (n=109) 
Demographics
   Age, years 60.71±11.33 63.54±7.55 NS
  (33-74) (36-77)
   Men, n (%) 131 (85) 88 (81) NS
Medical history 
   Hypertension, n (%) 55 (35) 40 (37) NS
   Diabetes, n (%) 46 (30) 30 (28) NS
   Dyslipidemia, n (%) 26 (17)  22 (20)  NS
Presentation
   Chest pain, n (%) 147 (95) 101 (93) NS
   Anterior location, n (%) 77 (50) 52 (48) NS
Fibrinolytic agent
   Streptokinase, n (%) 7 (4.5) 6 (5.5) NS
Post-fibrinolytic
TIMI-3 flow, n (%) 62 (40) 43 (39) NS
Post-fibrinolytic
CABG, n (%) 54 (35) 39 (36) NS
Death at 6 months, n (%) 12 (7.7) 2 (1.8) 0.048
Values are given as numbers/percentages or means±SD (range)
*Mann-Whitney-U test and Fisher’s exact test  
CABG - coronary artery bypass grafting, NS - nonsignificant, TIMI - thrombolysis in myo-
cardial infarction 
Table 1. Clinical characteristics of the patient groups  
Variables Study  Control p*
 subjects subjects 
 (n=109) (n=155)
Off hours, min 29 (19.37)  59 (31.93) <0.0001
(25th, 75th percentiles), n (n=79) (n=106) 
Regular hours, min 18 (12.26)  35 (22.74) <0.0001
(25th, 75th percentiles), n (n=30) (n=49) 
Values are given as medians (25th, 75th percentiles). 
Off hours: 5 PM to 8 AM and at weekends; regular hours: 8 am to 5 pm Monday-Friday. 
*Mann-Whitney-U test
Table 2. Time-to- treatment according to the time of the day  
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Our study showed that mortality was significantly reduced in 
the study group compared with the control group after the initiation 
of an optimal hospital organization. There was a significant reduc-
tion in DTN times after the introduction of the protocol. These 
included earlier transfer of fibrinolytic eligible patients from the 
field to the coronary care unit equipped for such therapy with an 
experienced staff, single-call activation of the CCU, and a well-
organized team-based approach with direct routing of patients to 
the CCU. These measures are consistent with the strategies articu-
lated by the door-to-treatment time workgroup (34). In addition, by 
earlier notification of a cardiologist, unnecessary multiple con-
sultations were avoided. Emergency room and CCU personnel 
were specifically trained. All these measures helped reduce 
time to treatment consistent with a previous report, which 
showed that in-hospital delay has been shortened by establish-
ing special in-hospital structures (8). Thus, one explanation for 
our finding is a greater extent of early myocardial salvage as the 
result of a shorter time to treatment. In an animal study, it has 
been shown that the final infarct size is very sensitive to the 
duration of ischemia before reperfusion (20). The ischemia time 
to recanalization also affects the severity of microvascular dam-
age (35). It has also been shown that there was a progressive 
decline in the extent of myocardium salvaged as the interval 
between symptoms and therapy increased (36). Earlier treat-
ment that improves myocardial (microvascular) reperfusion 
might have enhanced our patients’ survival. 
Thus, all efforts should be made to shorten total ischemic time. 
Coordinated efforts among community services, hospitals, and 
physicians will be necessary to achieve the goal of shortening 
time to treatment. Organizational culture, physician leadership, 
interrelationship between cardiology and emergency physicians 
and staff, emergency medical systems, and administrative support 
need to be identified and used by hospitals for performance 
improvement programs to decrease door-to-needle and decrease 
mortality from STEMI. Resources should be directed to early rec-
ognition of the acute myocardial infarction, improved utilization of 
emergency services for transportation, and prehospital diagnosis 
and triaging. The literature would suggest that prehospital 12-lead 
electrocardiogram and advanced emergency department notifi-
cation reduces in hospital time to fibrinolysis (37). McNamara et 
al. (11) found that improving time to fibrinolytic therapy could have 
an important effect on improving survival rates for patients pre-
senting with STEMI. Our results also further highlight the impor-
tance of reducing the time delay between symptom onset and the 
initiation of thrombolytic therapy in patients with AMI. Meaningful 
reductions in fibrinolytic treatment times can be achieved with a 
better organization at an institutional level. Moreover, this could 
translate into better patient outcomes. 
Study limitations 
Several limitations of this study should be mentioned. Its lim-
ited sample size is one of the weaknesses of the study. Information 
was obtained by direct telephone interview with patients who had 
not visited our outpatient clinic. Thus, we largely relied on their 
recollection for the events. Time to treatment was calculated from 
when the patient was first registered with the front desk in the ER 
to the initiation of fibrinolytic therapy in the CCU. Sometimes reg-
istration took place after patients’ transfer from the ER. Some 
patients might have discontinued their medications (beta- block-
ers, ACE-Is, statins) for some reason against our advice. 
Conclusion 
We implemented a protocol and achieved door-to-needle 
times that were close to what is recommended in the guidelines. 
We showed that mortality of patients presenting with STEMI 
was significantly reduced after a well-organized collaborative 
team approach has been implemented. We demonstrated that 
novel and simple strategies and coordination of systems of care 
make these times achievable and improve patients’ outcomes. 
Since fibrinolytic therapy remains the most accessible therapy 
for such patients, a well-organized collaborative team approach 
can be broadly applied to decrease their mortality. 
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